Analysis of "Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users".

Automated insulin delivery (AID) is now standard of care for managing type 1 diabetes (T1D), yet its role in type 2 diabetes (T2D) is still emerging. While only one AID system has earned regulatory approval for T2D as of January 2025, real-world studies have demonstrated promising results. The article "Performance of an Automated Insulin Delivery system in people living with type 2 diabetes and insulin resistance: first real-world evidence in 26,427 users" presents a large-scale analysis of the MiniMed 780G system in T2D across 73 countries. By categorizing users into four phenotypically distinct cohorts, the study highlights the system's adaptability, achieving consistent glycemic improvements across groups. Despite limitations in baseline data and clinical parameters, the findings reinforce AID as an effective and scalable therapy for insulin-requiring T2D.